

PUBLIC NOTICE

FDA/CSD/CPE/PNS/24/007

Clarification on Tobinco Pharmaceuticals Ltd. v. Food and Drugs Authority

Accra: August 15, 2024 -The Food and Drugs Authority (FDA) has noted with concern the manner in which the recent ruling in the case of Tobinco Pharmaceuticals Ltd. v. The Food and Drugs Authority is being reported in the media.

Some media reports suggest that the CEO, Dr Delese Darko, has been negligent in her actions, thus causing the Authority to suffer this loss.

For the avoidance of doubt, the Authority informs the public that this case stems from actions taken in 2013. Despite the claims made against the then CEO, Dr. Stephen Opuni, by the applicant, Tobinco Pharmaceuticals Ltd, the current leadership of the organisation have provided a defence to the courts at all material times.

The action initiated against the FDA in 2019 has consistently and vigorously been responded to by the FDA.

continued on next slide...

1 of 2

SWIPE LEFT 

www.fdaghana.gov.gh



Your Well-being, Our Priority.

  055112224/5

 fda@fda.gov.gh

  fdaghana  fdaghana_

PUBLIC NOTICE

Clarification on Tobinco Pharmaceuticals Ltd. v. Food and Drugs Authority

The FDA acknowledges the judgment delivered by the High Court. However, the Authority respectfully disagrees with the decision and intends to exercise its right to appeal.

The FDA remains committed to upholding the judicial process and adhering to the rule of law and will follow due process until the matter is fully resolved.

For all inquiries and concerns, please reach out to us through the contacts below.

Signed

Chief Executive Officer

Food and Drugs Authority

Your Well-being, Our Priority.

2 of 2

www.fdaghana.gov.gh



  055112224/5

 fda@fda.gov.gh



[fdaghana](https://twitter.com/fdaghana)



[fdaghana_](https://facebook.com/fdaghana)